Abstract
Background
We studied the prevalence of chronic liver diseases, including hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, as late effects of therapeutic regimens against childhood malignancies in Japan.
Methods
Patients were long-time survivors of acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia (ANLL), non-Hodgkin's lymphoma (NHL), neuroblastoma, and osteosarcoma, who had been treated and completed the Children's Cancer and Leukemia Study Group (CCLSG) protocols for more than 6 months at CCLSG participating institutions. The study was initially done in 1993, and as a follow-up study using a retrospective questionnaire in 1997.
Results
The overall prevalence of HCV infection in the 1993 study was 8.1% of 443 children. Among those long-term survivors in the 1993 study, 36 (8.1%) children (24 with ALL, 6 with ANLL, 2 with NHL, and 4 others) showed liver dysfunction. The details of the HCV-positive long-term survivors were 26 (13.3%) with ALL, 4 (12.9%) with ANLL, 1 (2%) with NHL, and 5 (3%) with others. The overall prevalence of HCV infection in the 1997 study at the same institutions was 0.6%. Only a slight reduction (5.6%) of HCV antibody positivity was noted in the 1997 follow-up study, while marked reduction (77.2%) of chronic liver disorders was noted during the same follow-up period in 623 children.
Conclusions
The high frequency of HCV hepatitis among ALL children is thought to be related to frequent blood transfusions. The 1997 study is the lowest reported prevalence of HCV hepatitis among children with leukemia and malignant diseases.
Similar content being viewed by others
References
Rossetti F, Cesaro S, Pizzocchero P, Cadrobbi P, Guido M, Zanesco L. Chronic hepatitis B surface antigen-negative hepatitis after treatment of malignancy. J Pediatr 1992; 121:39–43.
Fink FM, Höcker-Schulz S, Mor W, Puchhammer-Stöckl E, Hofmann H, Zoubeck A, Pawlowsky J, Höcker P, Gadner H. Association of hepatitis C virus infection with chronic liver disease in paediatric cancer patients. Eur J Pediatr 1993;152:490–492.
Locasciulli A, Alberti A, Rossetti F, Santamaria M, Santoro N, Madon E, Miniero R, Lo Cutro M, Tamaro P, Paolucci P. Acute and chronic hepatitis in childhood leukemia: a multicenter study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP). Med Pediatr Oncol 1985;13:203–206.
Ninomiya T. Late effects on long term survived children with acute leukemia. CCLSG 90-95 Research Reports 1996:95–97.
Katayama T. Studies on post-transfusion hepatitis: 1994 report of the Working Group of Chronic Hepatitis; Ministry of Health and Welfare of Japan. 1994;19–21.
Monteleone PM, Andrzejewski C, Kelleher JF. Prevalence of antibodies to hepatitis C virus in transfused children with cancer. Amer J Pediatr Hematol-Oncol 1994;16:309–313.
Schneppenheim R, Rautenberg P, Behnke H, Vietor K. Seroprevalence and significance of antibodies to hepatitis C virus in pediatric patients with malignant diseases. Klin Pädiatr 1991;203:273–275.
Gutensohn K, Knödler B, Zeller W, Krüger W, Eckardt N, Hossfeld DK, Kühnl P. Prävalenz des hepatitis-C-virus bei polytransfundierten patienten mit hämatologischen und onkologischen erkrankungen. Infusionstherapie 1992; 19:19–22.
Arico M, Maggiore G, Silini E, Bono F, Vigano C, Cerino A, Mondelli M. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood 1994;84:2919–2922.
Dibenedetto SP, Ragusa R, Sciacca A, Di Cataldo A, Miraglia V, D'Amico S, Lo Nigro L, Ippolito AM. Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukemia. Eur J Pediatr 1994;153:271–275.
Kostritsa SS, Kuzin SN, Khukhlovich PA, Shakhgil'dian IV, Doroshenko NV, Blinov VM, Loparen VN, Sukhanova LL, Gol'tsov VA, Drobeniuk ZhA, Savin EA. The detection of antibodies to the hepatitis C virus and to HBsAg in donors with viral hepatitis and cancerous diseases in the Republic of Moldova. Voprosy Virusologii 1994;39:93–94.
Paydas S, Aksu HSZ, Paydas S, Burgut R, Sagliker Y. The prevalence of anti-HCV positivity in patients undergoing haemodialysis or with malignant disease. BJCP 1994;48: 25–26.
Bakir TMF, Kurbaan KM, Al Fawaz I, Ramia S. Infection with hepatitis viruses (B and C) and human retroviruses (HTLV-1 and HIV) in Saudi children receiving cycled cancer chemotherapy. J Trop Pediatr 1995;41:206–209.
Amano Y, Nakahata T, Ochiai H, Koike K, Komiyama A. Hepatitis C in multi-transfused children with hematologic oroncologic disorders. Jpn J. Pediatr Hematol 1992;6:99–103.
Kitamura T, Oda I, Akazai A, Nishiuchi R, Harutsumi M, Seino Y, Kotani N, Kunitomi N. Evaluation of hepatitis C virus infection in children with hematologic malignancy by combined use of RT-PCR method and anti-HCV five antigen systems. Jpn J Pediatr 1993;97:2452–2457.
Nishioka K. Sero-epidemiologic study of chronic hepatitis: 1989 year report of the Working Group of Chronic Hepatitis; Ministry of Health and Welfare of Japan. 1989:6–14.
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494–1500.
Cesaro S, Rosseti F, De Moliner L, Crivellaro C, Zanesco L, Bortolotti F. Interferon for chronic hepatitis C in patients cured of malignancy. Eur J Pediatr 1994;153:659–662.
Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi A. Statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151–2156.
Author information
Authors and Affiliations
About this article
Cite this article
Sekine, I., Dobashi, H., Kogawa, K. et al. Hepatitis C virus infection and chronic liver diseases after treatment of malignant disease in children: A multicenter study from the Children's Cancer and Leukemia Study Group of Japan. Int J Clin Oncol 3, 247–252 (1998). https://doi.org/10.1007/BF02489841
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02489841